FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | | |
| Estimated average burden | | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* MCGLYNN MARGARET G | | | | | | 2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / | | | | | | | | | (Ch | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | | |
|--|--|--|---|---------|------------------------------|--|---|-----------------------------|---|-------------------|----------|----------------|--|--|--------------------------|---|--|---|--|--|--|--|
| | | | | | . <u>M</u> . | MA [VRTX] | | | | | | | | | | Officer (give title | | | Other (| · I | | |
| (Last) | , | , | (Middle) | | 3. [| Date (| of Earliest | t Tran: | sactio | on (Mon | th/D | av/Year) | | | \dashv | below |) | | below) | | | |
| C/O VERTEX PHARMACEUTICALS INCORPORATED | | | | | | | 2022 | | | (| | - , , | | | | | | | | | | |
| 50 NOR | THERN AV | 4. If | If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | 6. lı | 6. Individual or Joint/Group Filing (Check Applicable | | | | | | | | | |
| (Street) | | | | | | | T. II Antondinone, Date of Original Fried (Month Day) Teal) | | | | | | | | | | Line) | | | | | |
| (Street) BOSTON MA 02210 | | | | | | | | | | | | | | | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| (City) | (Si | tate) | (Zip) | | | | | | | | | | | | | | | | | | | |
| | | Tab | le I - Nor | า-Deriv | ative | e Se | curitie | s Ac | quir | red, D | isp | osed c | of, or E | ene | ficial | ly Owne | d | | | | | |
| 1. Title of Security (Instr. 3) 2. Trans Date (Month) | | | | | | 2A. Deemed Execution Date, if any (Month/Day/Year | | e, Transaction Code (Instr. | | | | | | Benefic Owned | es ially Following | Form (D) o | n: Direct r Indirect sstr. 4) | 7. Nature of Indirect Beneficial Ownership | | | | |
| | | | | | | С | Code V | , | Amount | ınt (A) or (D) Pı | | Price | Transac | Reported Transaction(s) (Instr. 3 and 4) | | | (Instr. 4) | | | | | |
| Common Stock 05/0 | | | | | 1/202 | /2022 | | | D | | 921 | 921 D | | (1) | 1 | 178 | | D | | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deeme Execution if any (Month/Da | Date, | 4. Transa Code (8) | | 5. Number of | | 6. Date Exercisal Expiration Date (Month/Day/Year | | ate | | 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4) | | | 8. Price of Derivative Security (Instr. 5) | 9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | ly C | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exerc | e rcisable | Ex Da | piration te | Title | or Nu of | ımber | | | | | | | |
| Deferred Stock Units | (2) | 05/01/2022 | | | A | | 921 | | | (2) | | (2) | Commo Stock | n | 921 | (1) | 5,609 |) | D | | | |
| Stock Option (Right to Buy) | \$276.17 | 05/01/2022 | | | A | | 4,462 | | 05/0 | 01/2022 | 04. | /30/2032 | Commo Stock | ⁿ 4 | ,462 | \$0.00 | 4,462 | 2 | D | | | |

Explanation of Responses:

- 1. Upon the vesting of restricted stock units granted to Ms. McGlynn on May 1, 2021, Ms. McGlynn deferred the receipt of 921 shares of common stock and received instead 921 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 921 shares of common stock in exchange for an equal number of deferred stock units.
- 2. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McGlynn's disability or death

Remarks:

/s/ Sabrina Yohai, Attorney-in-

** Signature of Reporting Person

Fact

05/03/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.